Birgit M. Reipert

Baxalta Innovations GmbH, Donau City Str. 7
Vienna, 1220, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications

The interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy.

The interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy.

Journal: Blood
Published: November 06, 2024

Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.

Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A.

Journal: Blood advances
Published: September 29, 2023

The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A.

The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A.

Journal: Thrombosis research
Published: July 19, 2023

Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients.

Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients.

Journal: Journal of clinical medicine
Published: December 30, 2022

Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.

Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.

Journal: Journal of thrombosis and haemostasis : JTH
Published: September 29, 2022

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells.

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells.

Journal: Frontiers in immunology
Published: June 22, 2022

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study.

Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study.

Journal: Blood advances
Published: May 12, 2022

Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages.

Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages.

Journal: Frontiers in immunology
Published: March 14, 2022

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.

Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.

Journal: The Journal of clinical investigation
Published: March 07, 2022

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication.

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication.

Journal: Blood advances
Published: February 08, 2022

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors.

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors.

Journal: Blood advances
Published: July 13, 2021

The soluble cytoplasmic tail of CD45 regulates T-cell activation via TLR4 signaling.

The soluble cytoplasmic tail of CD45 regulates T-cell activation via TLR4 signaling.

Journal: European journal of immunology
Published: February 22, 2021
Showing 1-12 of 48

Last Updated: 09/26/2026